PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Send a file File manager PDF Toolbox Search Help Contact



doucumetsoftrials.pdf


Preview of PDF document doucumetsoftrials.pdf

Page 1 2 34546

Text preview


7/26/2018

Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment - Tabular View - ClinicalTrials.gov

Estimated Primary

May 1, 2018 (Final data collection date for primary outcome measure)

Completion Date
Current Primary Outcome
Measures

Neonatal birth weight in grams [ Time Frame: At time of Delivery ]

ICMJE

(submitted: July 23, 2017)
Original Primary Outcome
Measures

Change History
Current Secondary
Outcome Measures

Same as current

ICMJE

ICMJE

(submitted: July 23, 2017)

No Changes Posted

The change in Doppler velocity indices, [ Time Frame: 24 week till 35 weeks ]
Fetal growth velocity [ Time Frame: weekly till time of delivery ]
Gestational age at delivery, [ Time Frame: at time of delivery ]
APGAR score [ Time Frame: at 1 and 5 min of life ]
Neonatal complication rates [ Time Frame: The first 28 day of delivery ]
respiratory distress syndrome, intraventricular hemorrhage (IVH),
neonatal necrotizing enterocolitis (NEC), neonatal anemia, and neonatal
blood transfusion
Neonatal ICU admission rate [ Time Frame: The first 28 day of delivery ]
the interval between the diagnosis and delivery [ Time Frame: at time of
delivery ]

Original Secondary
Outcome Measures

Current Other Outcome
Measures

ICMJE

Original Other Outcome
Measures

Same as current

ICMJE

ICMJE

Not Provided
Not Provided

 
Descriptive Information
Brief Title

ICMJE

Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction
Treatment

Official Title

ICMJE

Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction
Treatment

Brief Summary

comparing the effect of using sildenafil citrate and LMWH in treatment of cases of
IUGR due to placental insufficiency

Detailed Description

One hundred pregnant women with documented intrauterine growth restriction
due to placental insufficiency at 28-35 weeks of gestation will be distributed into
two groups:

https://www.clinicaltrials.gov/ct2/show/record/NCT03230162?term=sildenafil%2C+pregnant&rank=1&view=record

2/6